Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M88,120Revenue $M8,264Net Margin (%)11.7Altman Z-Score2.4
Enterprise Value $M118,849EPS $2.7Operating Margin %26.0Piotroski F-Score6
P/E(ttm)99.3Beneish M-Score-2.5Pre-tax Margin (%)14.4Higher ROA y-yY
Price/Book14.010-y EBITDA Growth Rate %10.5Quick Ratio4.9Cash flow > EarningsY
Price/Sales11.65-y EBITDA Growth Rate %55.9Current Ratio5.2Lower Leverage y-yN
Price/Free Cash Flow55.2y-y EBITDA Growth Rate %136ROA % (ttm)3.4Higher Current Ratio y-yY
Dividend Yield %--PEG1.7ROE % (ttm)18.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M342ROIC % (ttm)7.3Gross Margin Increase y-yY

Gurus Latest Trades with VRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRXKen Fisher 2015-06-30 Buy $197.39 - $241.73
($221.34)
$ 257.3016%New holding1,828
VRXBill Ackman 2015-03-31 Buy 25.84%$142.83 - $204.69
($177.4)
$ 257.3045%New holding19,473,933
VRXWallace Weitz 2015-03-31 Reduce-1.84%$142.83 - $204.69
($177.4)
$ 257.3045%Reduce 33.46%917,261
VRXSteve Mandel 2015-03-31 Reduce-1.62%$142.83 - $204.69
($177.4)
$ 257.3045%Reduce 32.50%5,569,460
VRXJohn Paulson 2015-03-31 Add1.6%$142.83 - $204.69
($177.4)
$ 257.3045%Add 293.70%2,050,000
VRXGlenn Greenberg 2015-03-31 Reduce-1.24%$142.83 - $204.69
($177.4)
$ 257.3045%Reduce 4.07%5,877,016
VRXGeorge Soros 2015-03-31 Sold Out -0.95%$142.83 - $204.69
($177.4)
$ 257.3045%Sold Out0
VRXChris Davis 2015-03-31 Reduce-0.74%$142.83 - $204.69
($177.4)
$ 257.3045%Reduce 46.50%1,877,040
VRXLou Simpson 2015-03-31 Add0.71%$142.83 - $204.69
($177.4)
$ 257.3045%Add 5.81%1,898,540
VRXJoel Greenblatt 2015-03-31 Reduce-0.26%$142.83 - $204.69
($177.4)
$ 257.3045%Reduce 77.83%65,531
VRXRuane Cunniff 2015-03-31 Reduce-0.18%$142.83 - $204.69
($177.4)
$ 257.3045%Reduce 0.71%34,089,378
VRXPrivate Capital 2015-03-31 Add0.06%$142.83 - $204.69
($177.4)
$ 257.3045%Add 0.86%295,320
VRXGlenn Greenberg 2014-12-31 Reduce-2.23%$113.56 - $146.39
($134.66)
$ 257.3091%Reduce 6.98%6,126,609
VRXSteve Mandel 2014-12-31 Reduce-1.39%$113.56 - $146.39
($134.66)
$ 257.3091%Reduce 24.90%8,250,886
VRXWallace Weitz 2014-12-31 Reduce-1.2%$113.56 - $146.39
($134.41)
$ 257.3091%Reduce 18.50%1,378,606
VRXJoel Greenblatt 2014-12-31 Buy 0.34%$113.56 - $146.39
($134.66)
$ 257.3091%New holding295,632
VRXRuane Cunniff 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 257.3091%Reduce 0.47%34,331,973
VRXLou Simpson 2014-12-31 Reduce-0.11%$113.56 - $146.39
($134.66)
$ 257.3091%Reduce 1.19%1,794,227
VRXGlenn Greenberg 2014-09-30 Add2.6%$106.73 - $130.26
($118.9)
$ 257.30116%Add 8.86%6,586,582
VRXLou Simpson 2014-09-30 Add1.01%$106.73 - $130.26
($118.9)
$ 257.30116%Add 12.40%1,815,916
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rosiello Robert L.Executive Vice President 2015-06-12Buy12,900$232.5110.01view
UBBEN JEFFREY W 2015-06-10Sell4,200,000$220.2416.14view
Farmer Ronald HaroldDirector 2015-06-09Buy1,000$260.63-1.86view
Mirovsky PavelEVP, Pres. & GM Valeant EMENA 2015-06-02Sell38,000$238.017.47view
Whitaker Anne ClemDirector 2015-05-26Buy7,500$234.679view
Chai-Onn Robert RoswellEVP, CLO, General Counsel 2015-05-04Sell90,938$222.5414.94view
Chai-Onn Robert RoswellEVP, CLO, General Counsel 2015-03-02Sell90,939$200.0127.88view
Farmer Ronald HaroldDirector 2014-12-12Buy500$160.4859.38view
UBBEN JEFFREY W 2014-12-10Buy250,000$140.0682.62view
STEVENSON KATHARINE BERGHUISDirector 2014-12-03Buy1,500$145.7375.52view

Quarterly/Annual Reports about VRX:

News about VRX:

Articles On GuruFocus.com
Gabelli ABC Fund Second Quarter Letter Jul 27 2015 
Acquisition in the Health Care Industry Increased Volatility Jun 27 2015 
Follow Bill Ackman in Valeant Pharmaceuticals Jun 19 2015 
Andreas Halvorsen Sells More Than Half of His Stake in Valeant Jun 18 2015 
My Top 3 Pharma Stock Picks Jun 09 2015 
Lou Simpson Adds Precision Castparts to Portfolio in First Quarter Jun 08 2015 
Jeff Ubben Adds to Stakes in Microsoft, Halliburton, Baker Hughes in First Quarter Jun 04 2015 
An Exclusive GuruFocus Interview With Value Investor Wally Weitz Jun 03 2015 
John Paulson's First-Quarter Moves Alter Largest And Most Valuable Stakes Jun 01 2015 
Thursday’s Pre-Market Insights: GoPro Inc (GPRO), NeoStem Inc (NBS), Valeant Pharmaceuticals Intl May 28 2015 

More From Other Websites
Morgan Stanley Lifts Target On Valeant From $235 To $284 Jul 27 2015
RedHill Biopharma Provides Update on RHB-106 Program Partnered with Salix Pharmaceuticals Jul 27 2015
Valeant, Starbucks Lead 5 IBD 50 Stocks Bucking Market Jul 24 2015
Biogen's Big-Volume Plunge Marks End Of 5-Year Run Jul 24 2015
Valeant (VRX) Beats on Q2 Earnings & Revenues, Ups View - Analyst Blog Jul 24 2015
Valeant Clears Buy Point, Paces Top Medical Stocks Jul 23 2015
3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates Jul 23 2015
Stock Market Today - 07/23/15 Jul 23 2015
Dealpolitik: Activism Makes Corporate Governance More Complex at Zoetis Jul 23 2015
Valeant Pharmaceuticals (VRX) Earnings Report: Q2 2015 Conference Call Transcript Jul 23 2015
Valeant 2Q results beat estimates sending stock up Jul 23 2015
Valeant 2Q results beat estimates sending stock up Jul 23 2015
Valeant Passes RBC as Canada’s Largest Company by Market Value Jul 23 2015
Valeant Pharmaceuticals: All That Deal Making Pays Off? Jul 23 2015
Valeant profit beats estimates as U.S. sales stay strong Jul 23 2015
Valeant Earnings Soar On M&A, Organic Sales Growth Jul 23 2015
Valeant Ups Views With Big Quarter Jul 23 2015
Valeant reports 2Q loss Jul 23 2015
Valeant reports 2Q loss Jul 23 2015
Valeant Pharmaceuticals Reports Second Quarter 2015 Financial Results Jul 23 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK